Literature DB >> 24282790

The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients.

Baris Afsar1.   

Abstract

BACKGROUND: Seroconversion following Hepatitis B virus (HBV) vaccine in hemodialysis (HD) patients has been shown to be suboptimal. Nutritional and immunological factors were shown to influence the seroconversion related to HBV vaccination in HD patients. Resistance to erythropoiesis stimulating agents (ESA) for correction of anemia has also been shown to be associated with nutrition and inflammation in these patients.
OBJECTIVES: The aim of the current study was to analyze the relationship between anti-HBs response and erythropoietin (EPO) resistance in HD patients. PATIENTS AND METHODS: Demographics, clinical characteristics, laboratory parameters and the data about vaccination status were obtained from dialysis charts and vaccination registries retrospectively. To calculate the EPO resistance ESA hypo responsiveness index (EHRI) was used. The EHRI was calculated through deviding the weekly dose of EPO by per kilogram of body weight divided by the hemoglobin level. Patients were divided into non-seroconversion (anti-HBs titers were < 10 IU/L) and seroconversion groups (anti-HBs titers were ≥ 10 IU/L) after completion of the four-dose vaccination schedule.
RESULTS: In total 97 patients were enrolled. For the entire group, stepwise linear regression analysis revealed that square root transformed anti-HBs levels were independently associated with age (P = 0.016), blood urea nitrogen (P = 0.019), high sensitive C-Reactive Protein (P = 0.009), and square root transformed EHRI (P = 0.019). Logistic regression analysis have also demonstrated that blood urea nitrogen (P = 0.002), creatinine (P = 0.046), albumin (P = 0.01) and square root transformed EHRI (P = 0.011) were independently related to seroconversion.
CONCLUSIONS: EPO resistance was negatively associated with anti-HBs levels and seroconversion. More studies are needed to highlight the underlying mechanisms regarding EPO resistance and response to HBV vaccination in HD patients.

Entities:  

Keywords:  Erythropoietin; Hepatitis B; Renal Dialysis; Vaccines

Year:  2013        PMID: 24282790      PMCID: PMC3830906          DOI: 10.5812/numonthly.8919

Source DB:  PubMed          Journal:  Nephrourol Mon        ISSN: 2251-7006


  25 in total

1.  Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002-2007.

Authors:  Kia E Armstrong; Heather M Bush; Jana D Collins; Dave J Feola; Glyn C Caldwell; Alice C Thornton
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2010 May-Jun

2.  Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.

Authors:  F Rahman; A Dahmen; S Herzog-Hauff; W O Böcher; P R Galle; H F Löhr
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

3.  Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio.

Authors:  Funda Sari; Hulya Taskapan
Journal:  Int Urol Nephrol       Date:  2011-08-02       Impact factor: 2.370

4.  Inflammation and resistance to treatment with recombinant human erythropoietin.

Authors:  Lucia Del Vecchio; Pietro Pozzoni; Simeone Andrulli; Francesco Locatelli
Journal:  J Ren Nutr       Date:  2005-01       Impact factor: 3.655

5.  Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better.

Authors:  Gerald DaRoza; Andrea Loewen; Ognjenka Djurdjev; Janet Love; Cathy Kempston; Shelley Burnett; Mercedeh Kiaii; Paul A Taylor; Adeera Levin
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

6.  Hepatitis B virus vaccine response in hemodialysis: baseline patient characteristics.

Authors:  Andrew I Chin
Journal:  Hemodial Int       Date:  2003-10-01       Impact factor: 1.812

7.  Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality.

Authors:  Juan M López-Gómez; José M Portolés; Pedro Aljama
Journal:  Kidney Int Suppl       Date:  2008-12       Impact factor: 10.545

Review 8.  Anaemia and inflammation: what are the implications for the nephrologist?

Authors:  Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

Review 9.  T cells and B cells in chronic renal failure.

Authors:  B Descamps-Latscha; L Chatenoud
Journal:  Semin Nephrol       Date:  1996-05       Impact factor: 5.299

10.  Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression.

Authors:  Madeleine V Pahl; Sastry Gollapudi; Lili Sepassi; Pavan Gollapudi; Reza Elahimehr; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-08-14       Impact factor: 5.992

View more
  7 in total

Review 1.  Immune response to hepatitis B vaccine among patients on hemodialysis.

Authors:  Gasim I Gasim; Abdelhaleem Bella; Ishag Adam
Journal:  World J Hepatol       Date:  2015-02-27

2.  Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis.

Authors:  Suwasin Udomkarnjananun; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Claudia Nader; Somchai Eiam-Ong; Bertrand L Jaber; Paweena Susantitaphong
Journal:  J Nephrol       Date:  2019-11-07       Impact factor: 3.902

Review 3.  Prevention of hepatitis B virus infection: from the past to the future.

Authors:  R Orlando; M Foggia; A E Maraolo; S Mascolo; G Palmiero; O Tambaro; G Tosone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-13       Impact factor: 3.267

Review 4.  Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

Authors:  Dede Sit; Bennur Esen; Ahmet Engin Atay; Hasan Kayabaşı
Journal:  World J Hepatol       Date:  2015-04-18

5.  Recommendations on RBC Transfusion in Infants and Children With Acquired and Congenital Heart Disease From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Jill M Cholette; Ariane Willems; Stacey L Valentine; Scot T Bateman; Steven M Schwartz
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

6.  Hepatitis B vaccination: needs a revision.

Authors:  Mohammad Saeid Rezaee-Zavareh; Behzad Einollahi
Journal:  Hepat Mon       Date:  2014-03-11       Impact factor: 0.660

7.  In reply to "the relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients".

Authors:  Seyfollah Beladimusavi; Fatemeh Hayati
Journal:  Nephrourol Mon       Date:  2013-11-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.